While 4-1BB monotherapy is capable of mediating significant tumor regressions and even cures of numerous types of established murine tumors (Table 1), targeting 4-1BB with agonist antibodies as a monotherapy in the clinic has only yielded modest frequencies of RECIST partial responses and stabilization of disease. Here, TNFRSF9 is linked to neoplasm.